Topic: Hemophilia B

Hemophilia A and B

Nov 2022 | Assessment

Intervontions of Interest: etranacogene dezaparvovec (CSL Behring) valoctocogene roxaparvovec (Roctavian ™; BioMarin) ICER reviewed valoctocogene roxaparvovec for hemophilia A in 2020 (Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value). In this review, the two interventions will be considered separately as if we were performing two independent reviews in two different populations. […]